Related Experiment Video
Updated: Mar 15, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
The Risk of Thromboembolism in Users of Antidepressants and Antipsychotics
Kasper Adelborg1,2, Jens Sundbøll1,2, Poul Videbech3
1Department of Clinical Epidemiology, Aarhus University Hospital, Skejby, Denmark.
Abstract:
Arterial and venous thromboembolism are common causes of morbidity and mortality in the Western world. Mental disorders are also highly prevalent with a lifetime risk of experiencing any psychiatric disease ranging between 32 % and 37 %. Depression and schizophrenia may increase the risk of thromboembolism through genetic, behavioral, and biological mechanisms. Treatment of psychiatric patients with psychotropic drugs is imperative to improve quality of life and to reduce morbidity and mortality. However, studies have shown that psychotropic drugs themselves may modify the risk of arterial and venous thromboembolism, which should be taken into consideration when using these drugs in clinical practice. This association is, however, multifactorial, complex and susceptible to several confounding factors. Psychotropic drugs are widely prescribed, also among patients with cardiovascular disease. Therefore, understanding the association with thromboembolism and the underlying pathophysiological mechanisms is of major importance and will be reviewed in this chapter.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Venous Thrombosis III: Interprofessional Care
Antidepressant Drugs: Overview
Drug Toxicity: Risk factors
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...